Literature DB >> 1702098

A deletion in the gene for glycoprotein IIb associated with Glanzmann's thrombasthenia.

C D Burk1, P J Newman, S Lyman, J Gill, B S Coller, M Poncz.   

Abstract

The platelet fibrinogen receptor is composed of a complex of glycoproteins (GP) IIb and IIIa on the surface of platelets. Deficient function of this receptor prevents normal platelet aggregation, resulting in Glanzmann's thrombasthenia (GT). In this paper, we describe a black thrombasthenic patient who is either homozygous or hemizygous for a deletion within the GPIIb gene. Initial Western blot analysis of platelet proteins from this patient did not detect any GPIIb, but did detect small amounts of GPIIIa of normal mobility. Quantitation of vitronectin receptor (VNR) demonstrated that this thrombasthenic patient had approximately 1.5-2 times the number of these receptors per platelet compared with controls, a finding that has previously been noted in other thrombasthenic patients with defects in GPIIb. Genomic Southern blot studies demonstrated a deletion in the GPIIb gene of approximately 4.5 kilobasepairs (kb). Analysis of the isolated GPIIb gene demonstrated that the deletion begins between two Alu repeats within intron 1 and ends in intron 9. Polymerase chain reaction (PCR) studies using platelet RNA and oligonucleotides directed to both the 5' and 3' ends of the GPIIb cDNA sequence easily detected GPIIb transcript, suggesting that the genomic deletion of exons 2-9 does not significantly decrease the level of the GPIIb mRNA. Sequence analysis of PCR-generated GPIIb cDNA showed that a cryptic AG splice acceptor sequence was being utilized, resulting in a transcript that contained a portion of introns 1 and 9, as well as having a deletion of exons 2-9. Unlike the GPIIb gene, the GPIIIa gene appears to be intact by Southern blot analysis. PCR studies using platelet RNA and oligonucleotides directed to the GPIIIa cDNA sequence demonstrated the presence of GPIIIa mRNA. In summary, the thrombasthenic state in this patient appears to be due to a GPIIb gene deletion resulting in an abnormal transcript and no detectable platelet GPIIb. Platelet GPIIIa levels were secondarily low presumably due to the known instability of GPIIIa in the absence of GPIIb.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1702098      PMCID: PMC295042          DOI: 10.1172/JCI114982

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  54 in total

1.  Structure of the platelet membrane glycoprotein IIb. Homology to the alpha subunits of the vitronectin and fibronectin membrane receptors.

Authors:  M Poncz; R Eisman; R Heidenreich; S M Silver; G Vilaire; S Surrey; E Schwartz; J S Bennett
Journal:  J Biol Chem       Date:  1987-06-25       Impact factor: 5.157

2.  Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor.

Authors:  D A Cheresh
Journal:  Proc Natl Acad Sci U S A       Date:  1987-09       Impact factor: 11.205

3.  Amino acid sequence of the vitronectin receptor alpha subunit and comparative expression of adhesion receptor mRNAs.

Authors:  S Suzuki; W S Argraves; H Arai; L R Languino; M D Pierschbacher; E Ruoslahti
Journal:  J Biol Chem       Date:  1987-10-15       Impact factor: 5.157

4.  Chromosomal localization of the genes for the vitronectin and fibronectin receptors alpha subunits and for platelet glycoproteins IIb and IIIa.

Authors:  D M Sosnoski; B S Emanuel; A L Hawkins; P van Tuinen; D H Ledbetter; R L Nussbaum; F T Kaos; E Schwartz; D Phillips; J S Bennett
Journal:  J Clin Invest       Date:  1988-06       Impact factor: 14.808

5.  Biosynthetic and functional properties of an Arg-Gly-Asp-directed receptor involved in human melanoma cell attachment to vitronectin, fibrinogen, and von Willebrand factor.

Authors:  D A Cheresh; R C Spiro
Journal:  J Biol Chem       Date:  1987-12-25       Impact factor: 5.157

6.  Efficient surface expression of platelet GPIIb-IIIa requires both subunits.

Authors:  T E O'Toole; J C Loftus; E F Plow; A A Glass; J R Harper; M H Ginsberg
Journal:  Blood       Date:  1989-07       Impact factor: 22.113

7.  Physical linkage of the genes for platelet membrane glycoproteins IIb and IIIa.

Authors:  P F Bray; G Barsh; J P Rosa; X Y Luo; E Magenis; M A Shuman
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

8.  Immunochemical and amino-terminal sequence comparison of two cytoadhesins indicates they contain similar or identical beta subunits and distinct alpha subunits.

Authors:  M H Ginsberg; J Loftus; J J Ryckwaert; M Pierschbacher; R Pytela; E Ruoslahti; E F Plow
Journal:  J Biol Chem       Date:  1987-04-25       Impact factor: 5.157

9.  A novel integrin (alpha E beta 4) from human epithelial cells suggests a fourth family of integrin adhesion receptors.

Authors:  S Kajiji; R N Tamura; V Quaranta
Journal:  EMBO J       Date:  1989-03       Impact factor: 11.598

10.  Amino acid sequence of the alpha subunit of human leukocyte adhesion receptor Mo1 (complement receptor type 3).

Authors:  M A Arnaout; S K Gupta; M W Pierce; D G Tenen
Journal:  J Cell Biol       Date:  1988-06       Impact factor: 10.539

View more
  12 in total

Review 1.  Demystified...adhesion molecule deficiencies.

Authors:  D Inwald; E G Davies; N Klein
Journal:  Mol Pathol       Date:  2001-02

2.  A new variant of Glanzmann's thrombasthenia (Strasbourg I). Platelets with functionally defective glycoprotein IIb-IIIa complexes and a glycoprotein IIIa 214Arg----214Trp mutation.

Authors:  F Lanza; A Stierlé; D Fournier; M Morales; G André; A T Nurden; J P Cazenave
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

3.  Activation of integrin-beta3-associated syk in platelets.

Authors:  S Sarkar; M M Rooney; S T Lord
Journal:  Biochem J       Date:  1999-03-15       Impact factor: 3.857

Review 4.  Do cell junction protein mutations cause an airway phenotype in mice or humans?

Authors:  Eugene H Chang; Alejandro A Pezzulo; Joseph Zabner
Journal:  Am J Respir Cell Mol Biol       Date:  2011-02-04       Impact factor: 6.914

5.  Truncation of the cytoplasmic domain of beta3 in a variant form of Glanzmann thrombasthenia abrogates signaling through the integrin alpha(IIb)beta3 complex.

Authors:  R Wang; S J Shattil; D R Ambruso; P J Newman
Journal:  J Clin Invest       Date:  1997-11-01       Impact factor: 14.808

6.  Glanzmann thrombasthenia resulting from a single amino acid substitution between the second and third calcium-binding domains of GPIIb. Role of the GPIIb amino terminus in integrin subunit association.

Authors:  D A Wilcox; C M Paddock; S Lyman; J C Gill; P J Newman
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

7.  Homologous recombination among three intragene Alu sequences causes an inversion-deletion resulting in the hereditary bleeding disorder Glanzmann thrombasthenia.

Authors:  L Li; P F Bray
Journal:  Am J Hum Genet       Date:  1993-07       Impact factor: 11.025

8.  Ser-752-->Pro mutation in the cytoplasmic domain of integrin beta 3 subunit and defective activation of platelet integrin alpha IIb beta 3 (glycoprotein IIb-IIIa) in a variant of Glanzmann thrombasthenia.

Authors:  Y P Chen; I Djaffar; D Pidard; B Steiner; A M Cieutat; J P Caen; J P Rosa
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

9.  Glanzmann thrombasthenia secondary to a Gly273-->Asp mutation adjacent to the first calcium-binding domain of platelet glycoprotein IIb.

Authors:  M Poncz; S Rifat; B S Coller; P J Newman; S J Shattil; T Parrella; P Fortina; J S Bennett
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

10.  Activation-dependent changes in human platelet PECAM-1: phosphorylation, cytoskeletal association, and surface membrane redistribution.

Authors:  P J Newman; C A Hillery; R Albrecht; L V Parise; M C Berndt; A V Mazurov; L C Dunlop; J Zhang; S E Rittenhouse
Journal:  J Cell Biol       Date:  1992-10       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.